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Abstract 41 
Acetaminophen (paracetamol) is a widely used analgesic and antipyretic drug with only 42 
incompletely understood mechanisms of action. Previous work, using models of acute 43 
nociceptive pain, indicated that analgesia by acetaminophen involves an indirect activation of 44 
CB1 receptors by the acetaminophen metabolite and endocannabinoid re-uptake inhibitor 45 
AM 404. However, the contribution of the cannabinoid system to anti-hyperalgesia against 46 
inflammatory pain, the main indication of acetaminophen, and the precise site of the relevant 47 
CB1 receptors have remained elusive. Here, we analyzed acetaminophen analgesia in mice of 48 
either sex with inflammatory pain and found that acetaminophen exerted a dose-dependent anti-49 
hyperalgesic action, which was mimicked by intrathecally injected AM 404. Both compounds lost 50 
their anti-hyperalgesic activity in CB1-/- mice confirming the involvement of the cannabinoid 51 
system. Consistent with a mechanism down-stream of pro-inflammatory prostaglandin formation, 52 
acetaminophen also reversed hyperalgesia induced by intrathecal prostaglandin E2 (PGE2). To 53 
distinguish between a peripheral/spinal and a supraspinal action, we administered 54 
acetaminophen and AM 404 to hoxB8-CB1-/- mice, which lack CB1 receptors from the peripheral 55 
nervous system and the spinal cord. These mice exhibited unchanged anti-hyperalgesia 56 
indicating a supraspinal site of action. Accordingly, local injection of the CB1 receptor antagonist 57 
rimonabant into the rostral ventromedial medulla (RVM) blocked acetaminophen-induced anti-58 
hyperalgesia, while local RVM injection of AM 404 reduced hyperalgesia in wild-type mice but 59 
not in CB1-/- mice. Our results indicate that the cannabinoid system contributes not only to 60 
acetaminophen analgesia against acute pain but also against inflammatory pain, and suggest 61 
that the relevant CB1 receptors reside in the RVM. 62 
 63 
 64 
Significance statement 65 
Acetaminophen is a widely used analgesic drug with multiple but only incompletely understood 66 
mechanisms of action including a facilitation of endogenous cannabinoid signaling via one of its 67 
metabolites. Our present data indicate that enhanced cannabinoid signaling is also responsible 68 
for the analgesic effects of acetaminophen against inflammatory pain. Local injections of the 69 
acetaminophen metabolite AM 404 and of cannabinoid receptor antagonists as well as data from 70 
tissue specific CB1 receptor deficient mice suggest the rostral ventromedial medulla as an 71 
important site of the cannabinoid-mediated analgesia by acetaminophen.  72 
73 
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Introduction 74 
In the past decades, several potential molecular mechanisms have been proposed that may 75 
explain how acetaminophen exerts its analgesic action. These include the inhibition of 76 
cyclooxygenases (COXs) (Flower and Vane, 1972; Hanel and Lands, 1982; Graham and Scott, 77 
2005), the activation of spinal serotonergic descending projections (Tjolsen et al., 1991; Pini et 78 
al., 1996), an involvement of the brain opioid system (Tjolsen et al., 1991; Herrero and Headley, 79 
1996; Pini et al., 1996; Sandrini et al., 2001), inhibition of nitric oxide generation (Bjorkman et al., 80 
1994; Bujalska, 2004), and activation of spinal TRPA1 channels by the acetaminophen 81 
metabolites N-acetyl-p-benzoquinoneimine (NAPQI) and p-benzoquinone (Andersson et al., 82 
2011). In addition, the generation of N-arachidonoylphenolamin (AM 404) from acetaminophen 83 
through deacetylation to p-aminophenol and the subsequent conjugation with arachidonic acid 84 
by central nervous system fatty amide hydrolase (FAAH) (Högestatt et al., 2005) has drawn the 85 
attention to a possible involvement of the endocannabinoid system. AM 404 increases tissue 86 
concentrations of the endocannabinoid arachidonoyl ethanolamide (AEA), also known as 87 
anandamide, through an inhibition of anandamide reuptake into neurons and astrocytes 88 
(Beltramo et al., 1997; Fegley et al., 2004). After spinal or systemic application, AM 404 exerts 89 
analgesic activity against acute pain, evoked by noxious chemical stimuli, as well as against 90 
inflammatory and neuropathic pain (Gühring et al., 2002; La Rana et al., 2006). In line with an 91 
important contribution of the endocannabinoid system, acetaminophen-mediated antinociception 92 
was lost in CB1 receptor-deficient (CB1-/-) mice (Mallet et al., 2008) as well as in mice lacking 93 
FAAH (FAAH-/- mice) (Mallet et al., 2010). Accordingly, acetaminophen-induced analgesia was 94 
also reduced by the FAAH inhibitor URB 597 (Mallet et al., 2008) and by the CB1 receptor 95 
antagonists AM 251 and rimonabant (Ottani et al., 2006; Dani et al., 2007; Mallet et al., 2008). 96 
The studies discussed above support a contribution of the endocannabinoid system to 97 
acetaminophen-mediated analgesia. However, most of these studies (Ottani et al., 2006; Mallet 98 
et al., 2008; Mallet et al., 2010) tested acetaminophen in models of acute nociceptive pain, i.e. 99 
pain evoked by acute noxious thermal, mechanical, or chemical stimuli applied to naïve animals 100 
in the absence of nociceptive sensitization by inflammation or neuropathy. These acute pain 101 
models only poorly reflect the clinical indications for acetaminophen, which is primarily used to 102 
treat mild inflammatory pain (Bradley et al., 1991). In fact, acute antinociceptive effects of 103 
acetaminophen in humans are rather vague or do not exist at all (Olesen et al., 2012; Tiippana 104 
et al., 2013). In the present study, we have analyzed the anti-hyperalgesic properties of 105 
acetaminophen in mice with inflammatory hyperalgesia and demonstrate a critical contribution of 106 
CB1 receptors to the effects of acetaminophen against inflammatory hyperalgesia. Additional 107 
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experiments with tissue-specific CB1-/- mice and local injections of AM 404 or the CB1 receptor 108 
antagonist rimonabant suggest that the CB1 receptors relevant for inflammatory anti-109 
hyperalgesia reside in the RVM which is a well-known site for endogenous pain control.  110 
 111 
Methods 112 
Mice. Experiments were performed in wild-type mice (C57BL/6J; www.jax.org/strain/000664), 113 
CB1-/- mice (genetic background C57BL/6N; (Marsicano et al., 2002); 114 
www.informatics.jax.org/allele/MGI:2182924), and hoxb8-CB1-/- mice (genetic background 115 
C57BL/6; (Witschi et al., 2010); http://www.informatics.jax.org/allele/MGI:4881836). hoxb8-CB1-/- 116 
mice were obtained by crossing mice carrying floxed CB1 receptor alleles (CB1fl/fl mice; 117 
www.informatics.jax.org/allele/MGI:3045419; Marsicano et al., 2003) with mice expressing in 118 
addition the cre recombinase in spinal cord neurons and glial cells as well as in neurons of the 119 
dorsal root ganglia (hoxb8-cre mice; Witschi et al., 2010). Behavioral experiments on hoxb8-CB1-120 
/- mice were performed with hoxb8-cre-negative CB1fl/fl littermates as “wild-type” controls. 121 
Animals were housed under controlled environmental conditions (22°C, 12/12 light/dark cycle) 122 
and were allowed to take food and water ad libitum. 123 
 124 
Behavioral testing. Experiments were performed in adult (7-9 week old) female and male mice. 125 
Mice were randomly assigned to treatment groups. On the first day of the experiments, each 126 
mouse was tested several times to obtain baseline paw withdrawal thresholds (PWTs). Animals 127 
were placed in Plexiglas boxes on a metal grid and allowed to accommodate to the test 128 
confinement for at least 1 hour prior to starting behavioral experiments. Mechanical sensitivity 129 
was measured using electronically controlled von Frey filaments (IITC, Woodland Hills, USA). At 130 
least 3 measurements were made for each time point. The experimenter was blind to the 131 
genotype or to the type of treatment (vehicle or drug) in all experiments. Permission for animal 132 
experiments was obtained from the Veterinäramt des Kantons Zürich (license 92/2007 and 133 
126/2012/16). 134 
Inflammatory hyperalgesia was induced using the yeast extract zymosan A (Meller and Gebhart, 135 
1997). Zymosan A (Fluka) was suspended in 0.9% NaCl and injected subcutaneously (0.06 mg / 136 
20 ?l) into the plantar side of the left hind paw 24 hours prior to the administration of 137 
acetaminophen or AM 404. Spinal PGE2-induced hyperalgesia was evoked through intrathecal 138 
injection of PGE2 (Sigma; 0.4 nmoles / 4 ?l, dissolved in 1% ethanol and 99% artificial 139 
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cerebrospinal fluid (aCSF)). Intrathecal injections were made 1 hour before application of 140 
acetaminophen. For details, see ref. (Reinold et al., 2005).  141 
 142 
Drug administration, intrathecal and intraRVM injections. Acetaminophen (Sigma) was dissolved 143 
in 0.9% NaCl. The acetaminophen-containing solution or vehicle (0.9% NaCl, 400 ?l) was given 144 
per os (p.o.) through stainless steel tubes (Delvo SA, Switzerland). Rimonabant (SR141716A; 145 
Tocris) (Rinaldi-Carmona et al., 1994) was dissolved in a mixture of 43% (vol/vol) DMSO, 43% 146 
aCSF and 14% ethanol. Injection volumes were 5 and 4 μl for AM 404 (Tocris) and PGE2, 147 
respectively. AM 404 (Tocris) was dissolved in 40% DMSO and 60% 0.9% NaCl. Intrathecal (i.t.) 148 
injections were performed under isoflurane anesthesia at the level of the lumbar spine using a 149 
Hamilton syringe (Ahmadi et al., 2001). A small amount of black ink (1% v/v) was added to 150 
permit post-hoc verification of proper i.t. injections. Injections into the rostral ventromedial 151 
medulla (RVM) were performed with stainless steel cannulas. Fully anaesthetized mice were 152 
placed in a Kopf stereotaxic frame and implanted with a cannula using the following coordinates 153 
which were calibrated to the cranial Bregma points: x= -5.7; y= 0; zcranium= +4.2. The cannula was 154 
fixed with dental cement and the cement was secured at the skull with 2 - 3 screws. The fixed 155 
cannula was used to insert a 30G needle attached to a Hamilton syringe 5.8 mm deep. A 156 
volume of 300 nl was injected. For post hoc verification of correct targeting of the RVM 1 % v/v 157 
Evans blue was included in the injection solution. 158 
 159 
Hepatotoxicity assays. Mice were treated p.o. with vehicle (0.9 % NaCl), 200, 300 or 400 mg/kg 160 
acetaminophen. Twenty four hours later, blood was collected after decapitation, and the liver 161 
was dissected. To quantify liver damage we determined the blood levels of three enzymes, 162 
alanine aminotransferase (ALT), aspartic aminotransferase (AST) and lactate dehydrogenase 163 
(LDH), that are released upon acute liver damage from hepatocytes into the blood stream using 164 
the UniCel DxC 800 Synchron Clinical Systems (Beckman Coulter, USA). Livers were put in 4% 165 
formalin overnight and subsequently embedded in paraffin. Tissue sections (3 μm) were cut and 166 
stained with hematoxilin-eosin following standard procedures (Fischer et al., 2008). Liver 167 
degeneration was defined by the presence of vacuolar degeneration and pink-red tissue 168 
discoloration due to sinusoidal congestion and apoptotic cell body formation, as described 169 
previously (Zhao et al., 2016). For quantification of liver degeneration, the ratio of venules 170 
surrounded by healthy or discoloured tissue was calculated. 171 
 172 
Immunohistochemistry and in situ hybridization. For immunohistochemistry, three mice of each 173 
genotype were deeply anesthetized with a mixture of 25 mg/ml ketamine, 5 mg/ml xylazine, and 174 
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0.1 w/w% promethazine in H2O (1 ml/100 g, intraperitoneal [i.p.]) and subsequently perfused 175 
transcardially through the ascending aorta with 0.9% NaCl for 2 min, followed by 100 ml of a 176 
fixative containing 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB; pH 7.4) for 177 
another 20 min. After perfusion, spinal cords and brains were immediately isolated and postfixed 178 
in 4% PFA for 2 hours and washed in 0.1 M PB. Transverse sections of the spinal cord at a 179 
lumbar level as well as coronal sections of the cerebral hemispheres and the cerebellum (all 50 180 
μm thick) were cut using a vibratome (Leica, VTS-1000). Free-floating sections were collected in 181 
0.1 M PB. For immunoperoxidase staining, the sections were first extensively washed in 0.1 M 182 
PB. To block endogenous peroxidase activity, sections were afterwards incubated in 1% H2O2 in 183 
0.1 M PB for 10 min and again washed in 0.1 M PB. Following washing in 0.05 M Tris-buffered 184 
saline (TBS; pH 7.4) conditioning Triton X-100 (TBST), the sections were blocked in 10% normal 185 
donkey serum (Vector Laboratories, Burlingame, USA) for 45 min. Sections were then incubated 186 
with polyclonal affinity-purified guinea pig anti-CB1 antibodies (1 : 250; ~1 μg/ml; Fukudome et 187 
al., 2004) at 4°C for 48 hours. The antibodies were dissolved in 0.05 M TBS. After multiple 188 
washings, the sections were treated in TBS with biotinylated goat anti-guinea pig IgG (1 : 300; 189 
Vector Laboratories) for 2 hours and after further washing in TBS incubated with avidin-190 
biotinylated horseradish peroxidase complex (1 : 500; Elite-ABC, Vector Laboratories) for 1.5 191 
hours. Development of the immunoperoxidase reaction was done with 3,3'-diaminobenzidine 192 
(DAB) as chromogen and 0.01% H2O2 dissolved in TB (pH 7.6). Sections were briefly 193 
submerged in chrome gelatin (0.05% chromium potassium sulfate dodecahydrate, 0.5% gelatin 194 
and 0.05% NaN3 in DW), dried, soaked in xylene (2 x 15 min), and covered in DePeX (SERVA). 195 
Sections containing the RVM were treated with 0.5% OsO4 in PB for 20 min at 4°C, dehydrated 196 
in an ascending series of ethanol and propylene oxide, and embedded in Durcupan (ACM, 197 
Fluka, Buchs, Switzerland) following DAB development. During dehydration, sections were 198 
treated with 1% uranyl acetate in 70% ethanol for 15 min at 4°C. Light microscopic analysis of 199 
immunostaining was carried out with a Nikon Eclipse 80i upright microscope. Micrographs were 200 
taken with a Nikon DS-Fi1 digital camera. 201 
 202 
Statistical analyses. Data are presented as mean ± SEM and n indicates the number of animals 203 
tested. For dose response curves, PWTs were transformed into % maximum possible effects (% 204 
MPE), with 0% and 100% being the inflamed pre-drug value and the full return to pre-205 
inflammation value, respectively. Data from the dose response relationship of acetaminophen 206 
and AM 404 were fitted to the Hill equation y = ymax  [(ymax  ymin)/(1 + (ED50/D)nH)]; with ymax, 207 
maximum %MPE reached with saturating doses; ymin = 0; D, actual dose; ED50 half-maximum 208 
effective dose; and nH, Hill coefficient. To compare the magnitude of antihyperalgesic effects of 209 
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acetaminophen or AM 404 in wild-type and CB1-/- mice or in the presence or absence of 210 
antagonists, areas under the curve (AUCs) were calculated for the changes of PWTs from pre-211 
drug baseline over 150 min or 80 min, following application of acetaminophen or AM 404, 212 
respectively. When more than two groups were compared, statistical analyses were done by 213 
one-way ANOVA followed by Bonferroni or Dunnett's post hoc tests or two-way ANOVA, when 214 
two factors were analyzed. In all other experiments, statistical analyses were performed using 215 
the unpaired Student’s t-test (two-tailed). Statistical significance was accepted for P ≤ 0.05.  216 
 217 
Results 218 
Anti-hyperalgesic actions of acetaminophen and AM 404 in inflammatory pain  219 
Because acetaminophen is an antipyretic analgesic whose main indication is mild inflammatory 220 
pain, we analyzed its analgesic effects in the zymosan A model of inflammatory pain (Meller and 221 
Gebhart, 1997; Reinold et al., 2005). Subcutaneous (sct) zymosan A injection (0.06 mg in 20 μl 222 
0.9% NaCl) into one hindpaw decreased mechanical PWT from 4.11 ± 0.06 g (mean ± SEM, n = 223 
30 mice) to 1.10 ± 0.06 g within 24 hours after injection. For first experiments we chose a dose 224 
of 200 mg/kg, p.o., because this dose has successfully been used in studies by others (e.g. 225 
Högestätt et al., 2005; Mallet et al., 2010; Dalmann et al., 2015; Gentry et al., 2015). 226 
Acetaminophen caused a time-dependent partial reversal of zymosan A-induced decreases in 227 
PWT. Acetaminophen reached a maximum effect at 60 to 80 min after administration (Fig. 1A). 228 
PWT in the contralateral non-inflamed paws were not affected. Accordingly, acetaminophen had 229 
no effects on PWT in naïve mice (Fig. 1B). Testing the effects of different doses of 230 
acetaminophen revealed significant anti-hyperalgesic effects at doses ≥ 30 mg/kg. Dose-231 
response curves (Fig. 1D) display % maximum possible analgesia determined for the time 232 
interval between 60 and 80 min after drug application. Data were fitted to the Hill equation 233 
revealing an ED50 of 30.1 ± 4.9 mg/kg and a maximal effect (Emax) of 44.3 ± 3.4 %.  234 
We next tested whether this anti-hyperalgesia would be mimicked by CNS injection of the 235 
acetaminophen metabolite AM 404. Different doses of AM 404 were injected directly into the 236 
mouse spinal canal 24 hours after zymosan A injection (Fig. 1E,F). Mechanical sensitivities were 237 
measured for 100 min at 20 min intervals. Similar to acetaminophen, AM 404 caused a 238 
significant dose-dependent increase in PWTs (Fig. 1E). Dose-response curves (Fig. 1F) reveal 239 
an ED50 was 2.55 ± 0.04 nmol and Emax of 46.2 ± 0.2%. These experiments demonstrate that 240 
acetaminophen and its metabolite AM 404 exert potent dose-dependent anti-hyperalgesic 241 
actions against inflammatory pain. 242 
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We also examined whether acetaminophen exerted behavioral effects that might interfere with 243 
the read-outs of pain tests (Fig. 1G,H). To this end, we assessed effects of acetaminophen on 244 
motor coordination and sedation in the rotarod test and on muscle strength in the horizontal wire 245 
test. At doses of 200 and 300 mg/kg (p.o.) acetaminophen did not impair performance in these 246 
two tests (for statistics see figure legends).  247 
 248 
Liver toxicity of acute treatment with acetaminophen  249 
Compared to clinically used doses in humans (1 g in a 70 kg person is equivalent to 15 mg/kg), 250 
the acetaminophen doses required in the present study to achieve at least 40% reduction in 251 
hyperalgesia (≥ 200 mg/kg) appear rather high. In humans, doses higher than 150 - 250 mg/kg 252 
may induce hepatotoxicity (Brunton et al., 2011). On the other hand, a 10 to 15-fold difference 253 
between effective doses in humans and rodents is not unusual given the much higher metabolic 254 
rate of mice (Sharma and McNeill, 2009). However, because this ratio provides only an estimate 255 
and may differ between drugs, we tested whether the doses employed here would cause acute 256 
liver toxicity in mice (Fig 2). We measured blood levels of alanine aminotransferase (ALT), 257 
aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) 24 hours after 258 
administration of different doses of acetaminophen (figure 2A-C). For all three enzymes, 259 
increases in enzyme activities were minor at a dose of 200 mg/kg and did not reach significance 260 
(ALT [IU/l]: 63 ± 10, 214 ± 104, 3624 ± 2010, for vehicle, 200 mg/kg and 300 mg/kg, 261 
respectively; AST [IU/l]: 281 ± 42, 457 ± 48.6, and 1349 ± 730; LDH [IU/l]: 1072 ± 170, 1674 ± 262 
147, 7498 ± 4663; for statistics see figure 2). At a dose of 300 mg/kg, blood levels of all three 263 
enzymes increased several-fold and increases became statistically significant for ALT. We also 264 
investigated potential changes in liver histology caused by acetaminophen (Fig. 2D). Tissue 265 
damage was quantified by counting the number of venules surrounded by healthy or discolored 266 
liver tissue per field of view. No detectable liver degeneration was observed after 200 mg/kg. At 267 
300 mg/kg, the number of venules in degenerating tissue was increased but this increase did not 268 
reach statistical significance. Statistically significant tissue damage was however found after 400 269 
mg/kg. Based on these results, we decided to perform all subsequent experiments with an 270 
acetaminophen dose of 200 mg/kg. 271 
 272 
Contribution of CB1 receptors to anti-hyperalgesia by acetaminophen  273 
In order to test for a possible contribution of the cannabinoid systems to acetaminophen and 274 
AM 404-mediated analgesia in inflammatory pain conditions, we tested the effects of 275 
acetaminophen and AM 404 in global CB1 receptor deficient (CB1-/-) mice with an inflamed 276 
hindpaw. Wild-type and CB1-/- mice did not differ in their baseline mechanical sensitivities (PWTs 277 
 - 9 - 
were 3.9 ± 0.1 g, n = 15 and 4.0 ± 0.09 g, n = 13), for naïve wild-type and CB1-/-, respectively) 278 
and developed similar inflammatory hyperalgesia (PWTs were 0.93 ± 0.10 g, n = 15, and 1.00 ± 279 
0.05 g, n = 13, for zymosan A injected wild-type and CB1-/- mice, respectively). Anti-hyperalgesic 280 
effects of acetaminophen were virtually absent in the CB1-/- mice. For statistical analyses, we 281 
calculated the area under the curve over time (AUC [g·h]) for the difference between post-drug 282 
PWTs and the pre-drug PWT baseline. AUCs were 0.30 ± 0.34 g·h, n = 6, versus 1.23 ± 0.16 283 
g·h, n = 8, in wild-type mice (P = 0.012, unpaired Student’s t-test) (Fig. 3A). We next assessed 284 
whether the anti-hyperalgesic action of the acetaminophen metabolite AM 404 would also be 285 
lost in CB1-/- mice (Fig. 3B). To this end, we injected 10 nmoles of AM 404 intrathecally. AM 404 286 
again reversed mechanical hyperalgesia in wild-type mice (AUC: 1.07 ± 0.14 g·h; n = 7) but 287 
completely failed to reduce hyperalgesia in CB1-/- mice (AUC: -0.22 ± 0.03 g·h, n = 6, P < 0.001, 288 
unpaired Student’s t-test). The lack of a pain-relieving action of acetaminophen and AM 404 in 289 
CB1-/- mice corresponds well with the reversal of acetaminophen- and AM 404-mediated 290 
analgesia by the CB1 receptor antagonists (inverse agonists) AM 251 and rimonabant described 291 
previously by others in different pain models (La Rana et al., 2006; Ottani et al., 2006; Dani et 292 
al., 2007; Mallet et al., 2008). It strongly suggests that anti-hyperalgesia by systemic 293 
acetaminophen requires activation of CB1 receptors. A lack of CB1 receptors during development 294 
may cause changes in neuronal circuits (Berghuis et al., 2007) that could potentially interfere 295 
with the actions of acetaminophen. In order to exclude this possibility, we tested whether 296 
systemic antagonism of CB1 receptors with rimonabant would recapitulate the effect of genetic 297 
ablation of CB1 receptors. Rimonabant (5 mg/kg, i.p.) administered immediately before 298 
acetaminophen indeed completely prevented the anti-hyperalgesic action of acetaminophen 299 
(Fig. 3C).  300 
 301 
Analgesic effect of acetaminophen in PGE2-induced inflammatory pain 302 
It has previously been suggested that acetaminophen might act through an inhibition of COX-303 
dependent prostaglandin formation in the central nervous system (Flower and Vane, 1972; 304 
Hanel and Lands, 1982; Chandrasekharan et al., 2002; Graham and Scott, 2005). To test 305 
whether acetaminophen reduces inflammatory hyperalgesia through a mechanism downstream 306 
of central prostaglandin production, we induced hyperalgesia through intrathecal PGE2 injection 307 
(Taiwo and Levine, 1986; Uda et al., 1990; Reinold et al., 2005). One hour after PGE2 injection 308 
(0.4 nmol), PWTs decreased from a baseline value of 3.50 ± 0.08 g to 0.90 ± 0.06 g (n = 13) 309 
(Fig. 4A). Acetaminophen (p.o., 200 mg/kg) but not vehicle (p.o. 0.9% NaCl) administered 1 hour 310 
after PGE2 injection partially reversed PGE2-induced hyperalgesia. The AUCs ([g·h]) were 311 
calculated between the post-drug PWTs and a straight line between the PWT at 1.5 and 4.0 312 
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hours after PGE2 injection. In wild-type mice, the average AUC (anti-hyperalgesia) in 313 
acetaminophen-treated mice (AUC: 1.51 ± 0.14 g·h, n = 7) was significantly higher than that of 314 
the vehicle treated group (AUC. 0.073 ± 0.073 g·h, n = 6 mice, P < 0.001, unpaired Student’s t-315 
test) (Fig. 4B). We also assessed the hyperalgesic effect of intrathecal PGE2 in CB1-/- mice and 316 
the potential reversal of PGE2-induced hyperalgesia by acetaminophen in these mice. PGE2 317 
induced the same level of hyperalgesia, but acetaminophen was again completely devoid of 318 
anti-hyperalgesic effects in CB1-/- mice. Average AUCs in acetaminophen-treated CB1-/- mice 319 
(AUC: 0.20 ± 0.58 g·h, n = 6) were virtually identical to those in vehicle-treated CB1-/- mice (AUC: 320 
0.064 ± 0.46 g·h, n = 6, P = 0.95, unpaired Student’s t-test). Two-way ANOVA yielded a 321 
significant genotype x treatment interaction F(1,25) = 5.46, P = 0.03. These results suggest that 322 
acetaminophen alleviates inflammatory hyperalgesia through a mechanism independent of 323 
prostaglandin formation. 324 
 325 
Ablation of CB1 receptors from the periphery and the spinal cord does not block anti-326 
hyperalgesia by systemic acetaminophen 327 
We next aimed at identifying the anatomical origin of acetaminophen-induced anti-hyperalgesia. 328 
Our first analyses concentrated on CB1 receptors in the spinal cord for two reasons. First, 329 
intrathecal injection of AM 404 mimicked the anti-hyperalgesia induced by systemic treatment 330 
with acetaminophen in several respects and, second, activation of spinal CB1 receptors inhibits 331 
transmission for nociceptive signals between primary nociceptors and second order dorsal horn 332 
neurons in vitro (Liang et al., 2004; Kato et al., 2012). The latter action might be considered a 333 
prime candidate mechanism for acetaminophen-induced anti-hyperalgesia. To distinguish a 334 
peripheral/spinal from a supraspinal site of action, we made use of hoxb8-CB1-/- mice, which 335 
were generated by crossing hoxb8-cre mice with CB1fl/fl mice. During development, hoxb8-cre is 336 
expressed in all DRG neurons and in all neurons and astrocytes of the spinal cord up to level 337 
C4. hoxb8-cre is however virtually absent from the brain (Witschi et al., 2010). We verified the 338 
specific ablation of CB1 receptors from the spinal cord by comparing CB1 receptor expression in 339 
the spinal dorsal horn and in the periaqueductal grey (PAG), a midbrain area rich in CB1 340 
receptors (Fig. 5). In wild-type (CB1fl/fl) mice, intense CB1 receptor staining was observed in the 341 
grey matter of the superficial dorsal horn and in the dorsolateral funiculus as well as around the 342 
cerebral aqueduct in the PAG (Fig. 5A,D,D?,G). This staining was completely absent in spinal 343 
cord and PAG sections obtained from global CB1-/- mice (Fig. 5B,E,E?,H) indicating the specificity 344 
of the CB1 receptor antibody (see also Nyilas et al., 2009). As expected, hoxb8-CB1-/- mice 345 
exhibited a drastic reduction in CB1 receptor expression in the spinal dorsal horn (Fig. 5C,F,F?), 346 
but not in the PAG (Fig. 5I). A side-by-side comparison of global CB1-/- and conditional hoxb8-347 
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CB1-/- mice showed some remaining CB1 immunoreactivity in the dorsal horn of the hoxb8-CB1-/- 348 
mice, especially in the most superficial layers of the dorsal horn, which might result from 349 
terminals of axons descending from supraspinal sites to the dorsal horn.  350 
In behavioral experiments, hoxb8-CB1-/- mice and wild-type (hoxB8-cre negative CB1fl/fl) 351 
littermates did not differ in their baseline sensitivity to mechanical stimulation (PWT were 4.21 ± 352 
0.10 g (n = 15) and 4.39 ± 0.07 g (n = 12) in naïve hoxb8-CB1-/- mice and CB1fl/fl littermates) and 353 
developed virtually identical inflammatory hyperalgesia with PWTs of 0.79 ± 0.07 g and 0.73 ± 354 
0.08 g in hoxb8-CB1-/- mice and CB1fl/fl littermates. Both genotypes also exhibited virtually 355 
identical anti-hyperalgesic responses to systemic acetaminophen treatment. AUC were 2.15 ± 356 
0.08 g·h (n = 6) and 1.59 ± 0.27 g·h (n = 6) for hoxB8-CB1-/- and cre-negative wild-type (CB1fl/fl) 357 
mice, respectively (Fig. 5J). Very similar results were obtained with AM 404. AUCs were 1.41 ± 358 
0.12 g·h (n = 9) and 1.38 ± 0.11 g·h (n = 6), for hoxB8-CB1-/- and cre-negative littermates (Fig. 359 
5K). Together with the complete lack of anti-hyperalgesia by acetaminophen and AM 404 in CB1-360 
/- mice, these results suggest that acetaminophen acted through CB1 expressed at supraspinal 361 
sites. Alternatively, acetaminophen might act via CB1 receptors expressed in the spinal cord on 362 
the terminals of neurons descending from supraspinal sites, which are not targeted by the 363 
hoxB8-cre (compare Fig. 5C,F,F’). To distinguish between these two possibilities we continued 364 
with local injections of AM 404 and of the CB1 receptor antagonist rimonabant. 365 
 366 
Local injection of rimonabant and AM 404 suggest a critical role of the RVM in anti-hyperalgesia 367 
by systemic acetaminophen. 368 
The RVM serves well-established roles in endogenous pain control (Heinricher and Fields, 2013) 369 
and as a site of action of centrally acting analgesic drugs including cannabinoid ligands (Meng et 370 
al., 1998; Suplita et al., 2005). We therefore tested whether the RVM was also involved in the 371 
anti-hyperalegsic actions of acetaminophen. To this end, we analyzed whether local injection 372 
into the RVM of the CB1 receptor antagonist rimonabant would interfere with anti-hyperalgesia 373 
by systemic acetaminophen (Fig. 6). Rimonabant (and vehicle) injections were made via chronic 374 
cannulas that had been pre-implanted into the RVM one week before the experiment. Proper 375 
RVM injections were verified by addition of a small amount of Evans Blue to the injection 376 
solution and post-hoc anatomical analysis of mouse brain sections (Fig. 6A,B). Injection of 377 
rimonabant (0.67 μg in 300 nl) completely prevented the anti-hyperalgesic action of systemic 378 
acetaminophen (200 mg/kg) (Fig. 6C,D). The AUCs were 4.89 ± 1.35 g·h (n = 5) versus 0.67 ± 379 
0.54 g·h (n = 6), in aCSF and rimonabant pretreated mice, respectively (P = 0.013, unpaired 380 
Student’s t-test). RVM injection of rimonabant per se did not affect inflammatory hyperalgesia 381 
and RVM injection of vehicle did neither affect the inflammatory hyperalgesia nor change the 382 
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anti-hyperalgesic response of acetaminophen. Injection of rimonabant or vehicle or cannula 383 
implantation into the RVM of naïve mice was tested in 5 - 7 mice per group. These interventions 384 
had no effect on mechanical pain response threshold (data not shown). We next tested whether 385 
the effect of acetaminophen would be mimicked by local RVM injection of AM 404. As expected, 386 
AM 404 (1 μg, equivalent to 2.5 nmoles) significantly alleviated inflammatory hyperalgesia in 387 
wild-type mice but not in CB1-/- mice (Fig. 6E,F). In naïve mice, RVM injection of AM 404 did not 388 
significantly change PWTs (4.65 ± 0.56 g versus 4.23 ± 0.36 g, for AM 404 and vehicle, P = 389 
0.54, n = 4 mice per group). In this series of experiments, we finally tested whether injection of 390 
acetaminophen into the RVM would reduce hyperalgesia (Fig. 6 G). Consistent with an only very 391 
low conversion of acetaminophen in AM 404 in the brain (Högestätt et al., 2005), acetaminophen 392 
(1 μg in 300 nl) failed to significantly change PWTs (n = 6).  393 
 394 
Distribution of CB1 receptor mRNA and protein in the RVM. 395 
In many parts of the CNS, cannabinoid receptors are located on presynaptic axon terminal 396 
where they control neuronal activity through the inhibition of neurotransmitter release. The 397 
experiments described above suggest that acetaminophen exerts its anti-hyperalgesia action 398 
through a perhaps indirect activation of antinociceptive fiber tracts descending from the RVM. To 399 
gain insights into the distribution of CB1 receptors at this site, we performed 400 
immunohistochemistry and in situ hybridization experiments in wild-type and global CB1-/- mice 401 
(Fig. 7). The immunohistochemical experiments revealed that CB1 receptors at the protein level 402 
were abundantly distributed throughout the RVM (Fig. 7A-D), which is consistent with a central 403 
role of the RVM in the CB1-mediated anti-hyperalgesic action of acetaminophen. In contrast, CB1 404 
receptor mRNA was only detected in a few selected cells in the RVM close to the midline (Fig. 405 
7E). No such cells were detected in tissue from CB1-/- mice (Fig. 7F). The low density CB1-406 
immunolabelling found in the dorsal horn of the spinal cord of hoxB8-CB1-/- mice (Fig. 5F,F’) 407 
likely reflects those descending fibers, which originate from the few RVM CB1 mRNA-expressing 408 
cells. 409 
 410 
Local ablation of CB1 receptors in the RVM does not prevent the anti-hyperalgesic actions of 411 
acetaminophen. 412 
The results obtained with local injection into the RVM of rimonabant and AM 404 suggest a 413 
critical role of the RVM in the anti-hyperalgesic actions of acetaminophen. The relevant CB1 414 
receptors in the RVM may either reside on RVM neurons themselves or may be located on axon 415 
terminals of neurons innervating the RVM. To distinguish between these possibilities, we 416 
selectively ablated receptors on intrinsic RVM neurons by local injection of CB1fl/fl mice with 417 
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adeno-associated virus (AAV) carrying a cre recombinase expression cassette. AAV-cre virus 418 
injections were performed one week before acetaminophen treatment. Successful cre-mediated 419 
ablation of the CB1 receptor gene was verified with real time RT-PCR. The number of CB1 420 
receptor transcripts in the RVM was reduced to about 25% (Fig. 8A). However, despite this 421 
significant down-regulation of CB1 receptors, acetaminophen-induced anti-hyperalgesia 422 
remained largely unaffected (Fig. 8B,C). These results suggest that the relevant CB1 receptors 423 
reside on axon terminals of neurons projecting to the RVM rather than on intrinsic RVM neurons.  424 
Figure 9 illustrates a possible scenario: AM 404 in the RVM would increase the concentration of 425 
endocannabnoids (anandamide and 2-AG) and thereby indirectly activate CB1 receptors on 426 
inhibitory neurons that project to the RVM to tonically inhibit antinociceptive fiber tracts 427 
descending to the spinal cord. Increased activation of CB1 receptors on these neurons will 428 
reduce GABA release and dis-inhibit endogenous descending pain control units. Since many of 429 
the descending fibers release serotonin (Heinricher and Fields, 2013), this scenario is consistent 430 
with previous reports proposing not only a central site of action of acetaminophen but also a 431 
contribution of spinal serotonin receptors (Pelissier et al., 1995; Bonnefont et al., 2005). 432 
  433 
Discussion 434 
Our study demonstrates that acetaminophen exerts anti-hyperalgesic actions in a mouse model 435 
of inflammatory pain consistent with previous experimental (Vinegar et al., 1976; McQueen et 436 
al., 1991; Abbadie and Besson, 1994) and clinical studies (Skjelbred et al., 1977; Bradley et al., 437 
1991; Bjornsson et al., 2003; Brandt et al., 2006). These previous data have shown analgesia in 438 
adjuvant-induced monarthritis or postoperative swelling and against secondary pain in oral 439 
surgery or osteoarthritic knee pain. Activity against inflammatory hyperalgesia and the well-440 
known antipyretic effect of acetaminophen have led researchers to speculate about an inhibitory 441 
action of acetaminophen on prostaglandin formation, e.g. through COX inhibition. However, 442 
acetaminophen is largely devoid of anti-inflammatory activity (Clissold, 1986; Bertolini et al., 443 
2006; Brunton et al., 2011), which is a hallmark effect of classical COX inhibitors. Significant 444 
activity against inflammatory hyperalgesia in the absence of general anti-inflammatory efficacy 445 
could be due to a specific inhibition of prostaglandin production in the CNS or to an analgesic 446 
mechanism independent of the inhibition of prostaglandin formation. Several studies have 447 
support a contribution of the endocannabinoid system. However, most of these studies used 448 
models of acute nociceptive pain, which do not necessarily permit conclusions about the 449 
mechanisms of anti-hyperalgesic actions. 450 
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As shown in a previous study from our group, zymosan A-induced hyperalgesia strongly 451 
depends on spinally produced PGE2 (Reinold et al., 2005). This model is therefore well-suited to 452 
investigate mechanisms of drugs with anti-hyperalgesic actions in inflammatory conditions and 453 
should permit a straightforward detection of prostaglandin-dependent drug actions. The reversal 454 
of inflammatory hyperalgesia by acetaminophen observed in our study would hence be 455 
consistent with a block of PGE2 production by acetaminophen. However, acetaminophen was 456 
still active when hyperalgesia was induced by local spinal injection of PGE2 favoring a 457 
mechanism different from inhibition of prostaglandin formation. Several results of the present 458 
study support instead the involvement of central CB1 receptors: the reversal of PGE2-induced 459 
hyperalgesia by acetaminophen was absent in CB1-/- mice, and both AM 404 and 460 
acetaminophen failed to reverse zymosan A-induced hyperalgesia in CB1-/- mice. Furthermore, 461 
the congruent pattern of efficacy of acetaminophen and of AM 404 in different (global and spinal 462 
cord-specific) CB1 receptor-deficient mouse lines supports the contribution of AM 404 to the anti-463 
hyperalgesic actions of acetaminophen. These results also correspond well with previous 464 
findings demonstrating that acetaminophen-induced analgesia was lost in FAAH-/- mice, which 465 
do not convert acetaminophen into AM 404 (Högestätt et al., 2005; Dalmann et al., 2015). 466 
However, neither the present nor previously published results (Ottani et al., 2006; Dani et al., 467 
2007; Mallet et al., 2008) exclude an involvement of COX-1 or COX-2 (Flower and Vane, 1972; 468 
Hanel and Lands, 1982; Muth-Selbach et al., 1999; Boutaud et al., 2002; Graham and Scott, 469 
2005). An ex vivo study performed in human volunteers demonstrated inhibition of COX-1 and 470 
COX-2 following the oral administration of acetaminophen (Hinz et al., 2008), and AM 404 has 471 
also been shown to block COX-1 and COX-2 in lipopolysaccharide-stimulated macrophages 472 
(Högestätt et al., 2005). In this context, it is important to note that COX-2 contributes to the 473 
metabolism of endocannabinoids (Yu et al., 1997; Kozak et al., 2000). The extent to which 474 
inhibition of COX-dependent endocannabinoid degradation or blockade of endocannabinoid 475 
transporters contribute to acetaminophen-induced analgesia remains to be determined.  476 
Our results can also be reconciled with a report by (Mallet et al., 2010), who have proposed a 477 
role of supraspinal TRPV1 receptors as additional targets in acetaminophen and AM 404-478 
induced analgesia. AM 404 is not only an inhibitor of anandamide reuptake but also an agonist 479 
at TRPV1 receptors (De Petrocellis et al., 2000). The observation that AM 404-induced 480 
analgesia was absent in TRPV1-/- mice and abolished by intracerebroventricular injection of the 481 
TRPV1 receptor antagonist capsazepine may suggest functional interactions of CB1 and TRPV1 482 
receptors in the CNS (Fioravanti et al., 2008). More difficult to reconcile with our findings is the 483 
report by (Andersson et al., 2011). These authors ascribe the analgesic action of acetaminophen 484 
to the activation of TRPA1 channels on the spinal terminals of nociceptive fibers by the 485 
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acetaminophen metabolites NPQI and p-benzoquinone, and a subsequent inhibition of 486 
transmitter release via primary afferent depolarization. Since anti-hyperalgesia by 487 
acetaminophen was retained in hoxb8-CB1-/- mice, an interaction of TRPA1 channels with CB1 488 
receptors cannot explain these findings. It is likely that distinct mechanisms underlie the acute 489 
analgesic and the anti-hyperalgesic actions of acetaminophen.  490 
Comparing the effects of classical cannabinoids with those of acetaminophen reveals similarities 491 
and differences. Classical cannabinoids exert a tetrad of actions in rodents, which includes 492 
analgesia, hypothermia, sedation (reduced locomotor activity), and catalepsy (Little et al., 1988). 493 
Analgesia, sedation and hypothermia do also occur in mice in response to acetaminophen 494 
(Mallet et al., 2010). While our data provide strong support for the involvement of cannabinoid 495 
signaling in acetaminophen-induced anti-hyperalgesia, cannabinoid independent actions are 496 
likely more relevant for the hypothermic and antipyretic effects of acetaminophen (Gentry et al., 497 
2015). Such CB1 receptor-independent mechanisms include the inhibition of hypothalamic COX 498 
by AM 404 (Högestätt et al., 2005) and the activation of TRPA1 via the acetaminophen 499 
metabolite NAPQI (Gentry et al., 2015). The mechanisms of acetaminophen-induced sedation in 500 
mice have not been identified so far and catalepsy is not seen in mice. Furthermore, the 501 
psychotropic actions seen with classical CB1 receptor agonists in humans do not occur with 502 
acetaminophen. Local differences in the conversion of the acetaminophen metabolite p-503 
aminophenol into pharmacologically active AM 404, caused for example by varying FAAH 504 
activity in different CNS regions, or differences in the local activity of endocannabinoid system 505 
may explain these discrepancies. Such differences may also account for another discrepancy. 506 
While a previous report has suggested that CB1 receptor agonists exert most of their analgesic 507 
action through CB1 receptors on peripheral nociceptors (Agarwal et al., 2007), our experiments 508 
in hoxB8-CB1-/-, which lack CB1 receptors also from these cells, suggest that this is not the case 509 
for acetaminophen (see also Dalmann et al., 2015).  510 
In our experiments, we also aimed at a better definition of the site of acetaminophen's action. To 511 
this end, we used hoxb8-CB1-/- mice, which lack CB1 receptors specifically from the spinal cord 512 
and peripheral sensory neurons. Because CB1 receptors are densely expressed on different 513 
types of intrinsic spinal dorsal horn neurons and on sensory fiber terminals (Tsou et al., 1998; 514 
Farquhar-Smith et al., 2000; Bridges et al., 2003; Hegyi et al., 2009; Nyilas et al., 2009), 515 
experiments first focused on a possible spinal site of action. However, the anti-hyperalgesia by 516 
acetaminophen were completely preserved in hoxb8-CB1-/- mice.  517 
At least two explanations may account for these findings. The CB1 receptors responsible for 518 
acetaminophen analgesia might reside on the spinal terminals of fibers descending from 519 
supraspinal sites which are spared from hoxb8-cre mediated gene deletion. This scenario is 520 
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consistent with the presence of CB1 receptors in the termination area of descending fiber tracts 521 
in spinal cords of hoxb8-CB1-/- mice, and with the efficacy of AM 404 after intrathecal injection. 522 
However, AM 404 might have diffused to supraspinal sites after lumbar intrathecal injection. 523 
Such diffusion has been demonstrated earlier for radioactively labeled morphine (Gustafsson et 524 
al., 1985). Alternatively, acetaminophen might act via CB1 receptors at supraspinal sites located 525 
e.g. in the brainstem, where the somata of descending antinociceptive fiber tracts are located. 526 
Our experiments with local injection of rimonabant and AM 404 into the RVM provide strong 527 
support for this scenario (see also Högestätt et al., 2005; Mallet et al., 2008; Mallet et al., 2010; 528 
Dalmann et al., 2015). According to these previous studies, acetaminophen acts through a CB1 529 
receptor-mediated reinforcement of descending serotonergic bulbospinal pathways originating 530 
from the RVM (Mallet et al., 2008) with subsequent activation of pain-suppressing serotonin 531 
receptors in the spinal cord (Tjolsen et al., 1991; Pelissier et al., 1995; Pini et al., 1996; 532 
Bonnefont et al., 2005). Our results are thus in line with the important role of supraspinal CB1 533 
receptors in stress-induced analgesia (Hohmann et al., 2005; Suplita et al., 2006).  534 
Strong CB1 receptor immune reactivity but weak in situ hybridization signals in the RVM suggest 535 
that the relevant CB1 receptors reside on processes of neurons that project to the RVM from 536 
other brain areas. In this scenario, it is likely that the acetaminophen metabolite AM 404 537 
promotes the activation of CB1 receptors on GABAergic axon terminals that tonically inhibit 538 
serotonergic antinociceptive fiber tracts descending from the RVM to the spinal cord. Since the 539 
periaqueductal grey (PAG) controls RVM activity via descending axons (Heinricher and Fields, 540 
2013), it is conceivable that the CB1 receptors relevant for the analgesic action of 541 
acetaminophen reside on the terminals of fibers reaching the RVM from the PAG. 542 
Acetaminophen would thus indirectly reduce GABA release from these projections and dis-inhibit 543 
descending serotonergic fibers to facilitate endogenous pain control.  544 
In summary, our results shed new light on the mechanisms and sites of action of the anti-545 
hyperalgesic action of the widely used analgesic acetaminophen. They support the involvement 546 
of the endocannabinoid system in the analgesic action of acetaminophen against inflammatory 547 
pain and identify the RVM and descending antinociceptive fiber tracts as a likely site and 548 
mechanism of action.  549 
550 
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Figure legends 731 
 732 
Fig. 1 Anti-hyperalgesic actions of acetaminophen (p.o.) and AM 404 (i.t.) in the zymosan A 733 
model of inflammatory hyperalgesia. (A) Partial reversal of reduction in PWT (g) by 734 
acetaminophen 200 mg/kg. n = 6 mice. (B) The same dose of acetaminophen had no significant 735 
effect on PWT in naïve mice. Unpaired Student’s t-test, P = 0.66, n = 5 and 7, for 736 
acetaminophen and vehicle, respectively. Horizontal line indicates the time interval used to 737 
determine the maximal effects. (C) Effects of different doses of systemic acetaminophen 738 
administered 24 hours following s.c. injection of zymosan A (n = 6 mice per dose) on mechanical 739 
PWTs quantified as percent maximal possible effect (% maximum possible analgesia; mean ± 740 
SEM). (D) Dose response curve. Average % maximum possible analgesia determined for the 741 
intervals 60 and 80 min after drug administration was calculated for each group and fitted to the 742 
Hill equation. *P ≤ 0.05, ***P < 0.001, ANOVA followed by Dunnett's post-hoc test, F (4,25) = 743 
10.11 with Fcrit = 2.76. (E,F) Same as (C,D) but intrathecal AM 404 (n = 6 mice per group). 744 
Average % maximum possible analgesia was determined for the time interval between 20 and 745 
40 min after drug injection. *P ≤ 0.05, ***P < 0.001, ANOVA followed by Dunnett's post-hoc test, 746 
F (4,25) = 25.15. (G,H) Impact of systemic acetaminophen on muscle strength (percent 747 
successful attempts in the horizontal wire test) (G) and on motor coordination (time on rotarod) 748 
(H) at 60 – 90 min after oral acetaminophen administration. No statistically significant effects 749 
were found in the two tests. (G) ANOVA followed by Dunnett’s post hoc test. F(2,22) = 1.46. P = 750 
0.33 and 0.92, for 200 and 300 mg/kg, n = 7 -8 mice. (H) F(2,22) = 1.43. P = 0.33 and 0.97, for 751 
200 and 300 mg/kg, n = 7- 8 mice.  752 
 753 
754 
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Fig. 2 Acute liver toxicity of acetaminophen. (A-C) Plasma levels of enzymatic markers of liver 755 
damage were quantified in mice 24 hours after p.o. treatment with vehicle, 200 mg/kg or 300 756 
mg/kg acetaminophen. Statistical comparisons were made with ANOVA followed by Dunnett’s 757 
post-hoc test. (A) ALT: F(2,21) = 2.55, P = 0.99 and 0.02, for 200 and 300 mg/kg, n = 6 – 8 758 
mice. (B) AST: F(2,21) = 2.67, P = 0.91 and 0.08, for 200 and 300 mg/kg, n = 7 – 8 mice. (C) 759 
LDH: F(2,20) = 5.28, P = 0.97 and 0.09, for 200 and 300 mg/kg, n = 7 – 8 mice. (D) Histological 760 
changes caused by acetaminophen treatment were assessed 24 hours after drug administration. 761 
The percent venules surrounded by discolored tissue was calculated. No significant changes 762 
were observed after 200 and 300 mg/kg, however 400 mg/kg caused statistically significant liver 763 
damage. F(3,20) = 6.05, P = 0.69, 0.78, and 0.014, for 200, 300 and 400 mg/kg, n = 6 mice for 764 
all four groups. Right micrographs show magnifications of the indicated areas with healthy tissue 765 
surrounding a venule in the section taken from a vehicle treated mouse (veh) and damaged 766 
tissue around a venue in the section prepared from a mouse treated with 400 mg/kg. Dotted line 767 
in the top left micrograph indicates the damage area around the venule in the center.  768 
 769 
Fig. 3 Effect of CB1 receptor ablation on the antihyperalgesic actions of by acetaminophen and 770 
AM 404. (A) Acetaminophen (200 mg/kg, p.o.). Time course of changes in PWT. Acetaminophen 771 
was given 24 hours after injection of zymosan A to wild-type mice (n = 6) and to CB1-/- mice (n = 772 
8). Bar chart: AUCs (g·h, mean ± SEM). *, P ≤ 0.05, unpaired Student's t-test. (B) AM 404 (10 773 
nmol, i.t.) was administered 24 hours after injection of zymosan A in wild-type and CB1-/- mice (n 774 
= 7 each). ***P < 0.001, unpaired Student's t-test. (C) Systemic pretreatment with rimonabant 775 
(rim, 5 mg/kg, i.p.) completely blocked anti-hyperalgesia by acetaminophen. Two-way ANOVA 776 
F(1,22) = 9.08, P = 0.007 for pretreatment x treatment interaction, n = 4 – 8 per group. **, P < 777 
0.01, n = 6 and 8 mice for vehicle and rimonabant pretreated mice (unpaired Student’s t-test). 778 
 779 
Fig. 4 Effect of acetaminophen (200 mg/kg, p.o.) on mechanical hyperalgesia evoked by 780 
intrathecal PGE2 (0.4 nmol) in wild-type and CB1
-/- mice. (A) Change in PWTs (mean ± SEM). 781 
PGE2 was injected i.t. at time 0. Acetaminophen or vehicle were given p.o. (1 hour after PGE2 782 
injection. n = 7 and 6 for acetaminophen and vehicle, respectively. (B) AUC (mean ± SEM). 783 
Two-way ANOVA yielded a significant genotype x treatment interaction F(1,25) = 5.46, P = 0.03. 784 
n = 6 - 7 mice per group. 785 
 786 
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Fig. 5 Morphological and behavioral analysis of hoxb8-CB1-/- mice. (A-I) CB1 receptor expression 787 
in the spinal dorsal horn and PAG of wild-type, CB1-/- and hoxb8-CB1-/- mice. (A) High density of 788 
CB1 receptor-immunostaining is found in the superficial layers in the dorsal horn of wild type 789 
(CB1fl/fl) mouse spinal cord. (D,D’) At higher magnification, an abundant punctate staining pattern 790 
corresponding mostly to axon terminals is observed. (B,E,E’) The specificity of this staining 791 
pattern is validated by the complete lack of immunostaining on spinal cord sections derived from 792 
global CB1-/- animals. (C,F,F’) Deletion of CB1 receptors from DRG and spinal neurons as well as 793 
from astrocytes in hoxb8-CB1-/- animals did not fully eliminate CB1 receptor immunostaining. A 794 
remaining weak staining pattern was found in lamina I and II, where most descending 795 
monoaminergic fibers terminate. (G) Immunostaining for CB1 receptors in the midbrain 796 
periaqueductal grey nucleus (PAG) is concentrated around the dorsal and central part of the 797 
PAG. (H) This staining pattern is completely eliminated in the global CB1-/- animals, but remains 798 
fully intact in hoxB8-CB1-/- mice. Similar results were obtained in three mice of both genotypes. 799 
Scale bars are: (C valid also for A,B) 100 μm; (F applies also for D,E) 20 μm; (F’ applies also for 800 
D’,E’) 10 μm; and (I valid also for G,H) 200 μm. (J,K) Behavioral analysis. Changes in PWTs 801 
induced by the acetaminophen (200 mg/kg, p.o., J) in hoxb8-CB1-/- (n = 6) and wild-type (CB1fl/fl) 802 
mice (n = 6), and by AM 404 (10 nmol, i.t., K) in hoxb8-CB1-/- (n = 6) and wild-type (CB1fl/fl) mice 803 
(n = 9). Acetaminophen and AM 404 were administered 24 hours after zymosan A injection. 804 
Differences in AUCs were statistically insignificant (unpaired Student's t-test). 805 
 806 
Fig. 6 Local RVM injection of rimonabant blocks and local RVM injection of AM 404 mimics the 807 
anti-hyperalgesic action of systemic acetaminophen. 808 
(A) Sagittal brain section taken from a mouse after RVM injection verifies proper local RVM 809 
injection procedures. Red, Evans Blue; blue, DAPI (B) Respective brain regions (sagittal section 810 
at -0.04 mm) redrawn and simplified from Paxinos and Franklin (2001) for comparison. (C,D) 811 
Local injection of rimonabant (0.67 μg in 300 nl) prevented anti-hyperalgesia by systemic 812 
acetaminophen. Cannulation of the RVM, and injection of vehicle or rimonabant were per se 813 
without effect on mechanical pain thresholds. (C) Time course. (D) Two-way ANOVA revealed a 814 
significant pretreatment x treatment interaction. (F(1,23) = 10.8, n = 5 – 7 mice per group P < 815 
0.004). *, P < 0.05, unpaired Student’s t-test, acetaminophen in aCSF (n = 5) or rimonabant (n = 816 
6) pretreated mice. (E,F) Local injection of AM 404 (1 μg in 300 nl) into the RVM mimicked 817 
acetaminophen-induced anti-hyperalgesia. (E) Time course. (F) Statistics. ANOVA followed by 818 
Bonferroni post hoc test. F(2,17) = 13.4. ***, P ≤ 0.001, n = 6 mice per group. (G) Local injection 819 
of acetaminophen (1 μg in 300 nl) into the RVM had no effect on paw withdrawal threshold.  820 
 821 
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Fig. 7 CB1 receptor immunoreactivity and in situ hybridization in the RVM. 822 
(A,B) CB1 receptor immunoreactivity in coronal sections through the brainstem of wild-type (A) 823 
and CB1-/- mice (B). The lack of brownish color of the DAB precipitate in the CB1-/- tissue (B) 824 
confirms the specificity of CB1 immunolabeling. Squares indicate the area of the RVM shown at 825 
hight magnification in (C-F). (C) CB1 protein is present in high density within the RVM of wild-826 
type mice. Note the dense DAB puncta around the cell bodies, which are always devoid of 827 
labeling. (D) No CB1 immunostaining can be found in control sections from CB1-/- mice, which 828 
were processed together with the wild-type sections throughout the whole immunostaining 829 
procedure. The dark yellow color of the white matter bundles is due to an osmification step of 830 
tissue dehidration. (E) CB1 in situ hybridization signal in the RVM. Only a few scattered neurons 831 
(blue) express CB1 receptor mRNA at rather low levels. (F) No labelled cells are present in 832 
control sections prepared from CB1 receptor-deficient mice. Scale bars are 250 μm in A,B; 50 833 
μm in C-F. 834 
 835 
Fig. 8 Local knock-down of CB1 receptor expression in intrinsic RVM neurons fails to prevent 836 
acetaminophen-induced anti-hyperalgesia.  837 
(A) Changes in CB1 receptor mRNA levels seven days after AAV-cre injection in CB1fl/fl mice. 838 
mRNA levels have been normalized to ?-actin mRNA copy numbers. **, P < 0.01. n = 19 and 14, 839 
for AAV-Cre and AAV-GFP, respectively. Unpaired Student’s t-test. (B) Anti-hyperalgesia by 840 
acetaminophen (200 mg/kg). RVM cannula implantation and AAV-cre injections were made 7 841 
days before acetaminophen treatment. Zymosan A was injected 1 day, before acetaminophen 842 
treatment. Mechanical PWTs were determined before AAV-cre injection, after zymosan A 843 
injection, and after acetaminophen or vehicle administration. (C) Statistical analyses. 844 
Comparisons of acetaminophen effects in the three treatment groups (AAV-cre, AAV-eGFP, 845 
sham operated mice) revealed significant acetaminophen versus vehicle effects (*, P < 0.05, n = 846 
6 – 8 / group) but no significant treatment x pretreatment interaction (two-way ANOVA F(2,39) = 847 
0.41, P = 0.67). 848 
 849 
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Fig. 9 Hypothetical scheme of the central site of action of acetaminophen in inflammatory pain 851 
conditions. 852 
AM 404 produced from systemically administered acetaminophen increases the concentration of 853 
endocannabinoids (AEA and 2-AG) in the RVM by inhibiting their uptake or degradation. This 854 
increase activates CB1 receptors on axon terminals of neurons projecting to the RVM from 855 
upstream brain regions such as the PAG. These terminals normally release GABA to tonically 856 
inhibit serotonergic antinociceptive fiber tracts, which descend from the RVM to the spinal cord. 857 
Increased activation of CB1 receptors in the RVM would then reduce GABA release in the RVM 858 
and dis-inhibit descending pain control units. For a detailed discussion on the role of 859 
serotonergic neurons in the RVM, see (Heinricher and Fields, 2013). 860 
 861 
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